KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Net Margin (2016 - 2025)

Historic Net Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to 23.49%.

  • Supernus Pharmaceuticals' Net Margin fell 454000.0% to 23.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.8%, marking a year-over-year decrease of 119500.0%. This contributed to the annual value of 11.16% for FY2024, which is 109400.0% up from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Net Margin stood at 23.49%, which was down 454000.0% from 13.6% recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Net Margin registered a high of 21.91% during Q3 2024, and its lowest value of 23.49% during Q3 2025.
  • For the 5-year period, Supernus Pharmaceuticals' Net Margin averaged around 5.28%, with its median value being 4.6% (2022).
  • Its Net Margin has fluctuated over the past 5 years, first surged by 323200bps in 2024, then plummeted by -454000bps in 2025.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Net Margin stood at 1.54% in 2021, then surged by 892bps to 15.23% in 2022, then plummeted by -95bps to 0.72% in 2023, then surged by 1135bps to 8.83% in 2024, then tumbled by -366bps to 23.49% in 2025.
  • Its last three reported values are 23.49% in Q3 2025, 13.6% for Q2 2025, and 7.9% during Q1 2025.